Lotte Chemical Corporation (011170) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
10 Sep, 2026Executive summary
Q3 2025 revenue reached KRW 4.7861 trillion, with operating income turning positive at KRW 133 billion, reversing a prior loss, and net income at KRW 167 billion, reflecting sequential improvement.
For the first nine months of 2025, revenue was KRW 13.77 trillion, down from KRW 19.89 trillion year-over-year, with an operating loss of KRW 510 billion and net loss of KRW 881 billion.
Structural improvements and business portfolio transformation are ongoing, including participation in government-led industry restructuring and divestment of non-core assets.
Financial highlights
As of Q3 end, assets totaled KRW 33 trillion, liabilities KRW 14 trillion, capital KRW 19 trillion, and debt to equity ratio was 75.7%.
EBITDA for Q3 2025 was KRW 285 billion, up from KRW 48 billion in Q2 2025.
Cash and equivalents decreased to KRW 2.72 trillion at period end.
Non-core asset sales, including the Pakistan PTA business for $15 million, are expected to strengthen financial stability and improve liquidity.
Outlook and guidance
Feedstock prices are expected to remain stable in Q4, but global demand is projected to stay weak due to macroeconomic uncertainties.
CapEx will be maintained within EBITDA levels, with future investments focused on profitability and essential needs.
Strategic focus remains on expanding specialty materials, battery materials, and hydrogen-related businesses.
Advanced materials and fine chemicals segments are expected to maintain solid profitability through high value-added products.
Latest events from Lotte Chemical Corporation
- Q2 2024 sales rose, losses narrowed, and strategic investments in hydrogen and batteries continued.011170
Q2 2024 - Impairment losses led to deep 2024 losses, but gradual recovery and asset-light progress are expected.011170
Q4 2024 - Q3 2024 revenue was flat, losses widened, and asset sales and investments continue amid weak demand.011170
Q3 2024 - Q1 2025 losses narrowed as advanced and fine chemicals improved, but margin pressures persist.011170
Q1 2025 - Losses widened, but recovery is expected as portfolio shifts and new projects progress.011170
Q2 2025 - 2025 saw losses from weak demand and impairments, but recovery is expected through diversification.011170
Q4 2025 - Q2 2026 delivered higher profits and restructuring progress, despite ongoing market risks.011170
Q2 2026 - Q1 2026 returned to profit with KRW 4.99T revenue and KRW 49.6B net income amid ongoing risks.011170
Q1 2026